title: MRI-guided, open trial of abciximab for ischemic stroke within a 3- to 24-hour window.
abstract: The authors assessed the effect of IV abciximab on early neurologic improvement and ischemic lesion growth in 29 patients with supratentorial stroke and NIH stroke scale score (NIHSSS) > or = 4 (11.1 +/- 5.9), treated within 3 to 24 (13.6 +/- 5.5) hours of onset. The 48 to 72-hour NIHSSS improvement was 4.4 +/- 3.2 and the 24-hour lesion growth on DWI was +23% (-50%, +103%); 7/26 (27%) patients experienced lesion size decrease. Treatment of sub-24-hour stroke with abciximab improves early post-treatment neurologic status and often attenuates ischemic lesion growth.
authors.affiliation: Department of Neurology, Henry Ford Health Sciences Center, Detroit, Michigan, USA. mitsias@neuro.hfh.edu
authors.forename: P D
authors.initials: PD
authors.lastname: Mitsias
authors.forename: M
authors.initials: M
authors.lastname: Lu
authors.forename: B
authors.initials: B
authors.lastname: Silver
authors.forename: D
authors.initials: D
authors.lastname: Morris
authors.forename: J R
authors.initials: JR
authors.lastname: Ewing
authors.forename: S
authors.initials: S
authors.lastname: Daley
authors.forename: C
authors.initials: C
authors.lastname: Lewandowski
authors.forename: A
authors.initials: A
authors.lastname: Katramados
authors.forename: N I
authors.initials: NI
authors.lastname: Papamitsakis
authors.forename: H B
authors.initials: HB
authors.lastname: Ebadian
authors.forename: Q
authors.initials: Q
authors.lastname: Zhao
authors.forename: H
authors.initials: H
authors.lastname: Soltanian-Zadeh
authors.forename: D
authors.initials: D
authors.lastname: Hearshen
authors.forename: S C
authors.initials: SC
authors.lastname: Patel
authors.forename: M
authors.initials: M
authors.lastname: Chopp
mesh_terms: D000077284:Abciximab; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001921:Brain / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D002545:Brain Ischemia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002536:Cerebral Arteries / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage* / Q000009:adverse effects; D007262:Infusions, Intravenous; D020300:Intracranial Hemorrhages / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab